Poisoned in the Womb: When Medicine's Mistakes Echo Through Generations - Jill Escher (#19)
26 June 2025
With Jill Escher
Global
Jill Escher, president of the National Council on Severe Autism, traces her own sons' profound autism to synthetic steroid hormones administered to her mother during pregnancy in the 1960s. Her research connects decades of prenatal hormone exposure—from DES to anti-miscarriage drugs used until 2023—to rising rates of both autism and gender dysphoria. The episode raises hard questions about epigenetic harm, institutional silence and the medical establishment's repeated failure to learn from its own mistakes.
Jill Escher came to this research as a mother, not a detached academic. Her two sons are profoundly autistic, and for years the cause eluded her. The answer arrived in a set of medical records showing that her mother had received weekly injections of synthetic steroid hormones during her 1965 pregnancy. That discovery became the lens through which Escher now reads a much larger story: one about prenatal drug exposure, epigenetic inheritance, and a neurodevelopmental crisis that mainstream medicine has been persistently reluctant to interrogate. The episode situates her personal case within a well-documented historical disaster. Diethylstilbestrol, the synthetic oestrogen known as DES, was prescribed to millions of pregnant women across the mid-twentieth century to prevent miscarriage. It was eventually withdrawn after it was linked to rare cancers and reproductive abnormalities—most notoriously in the daughters of women who took it. Escher draws attention to the broader class of synthetic steroid hormones prescribed in similar contexts, some of which, she notes, remained in clinical use until 2023. The pattern she identifies is one of signals ignored, harm acknowledged late, and insufficient lessons carried forward. The scientific argument concerns epigenetics: changes in gene expression that leave the DNA sequence intact but can alter how that sequence is read, including across generations. Escher argues that prenatal exposure to certain synthetic hormones can reshape the developing brain in ways that vary by timing, dose, and individual vulnerability. The claim is not genetic determinism but probabilistic: exposure raises the likelihood of particular neurodevelopmental profiles, among them autism spectrum conditions. She is a lay advocate drawing on published research, not a bench scientist, and the episode is frank about the extent to which the underlying hypothesis remains inadequately studied. Where the episode intersects most directly with gender medicine is in Escher's observation that rates of autism and gender dysphoria have risen in parallel, and that neurodivergent individuals are substantially over-represented among young people presenting at gender clinics. She is careful not to claim a simple causal chain, but she asks a question that organised medicine appears reluctant to pursue: if prenatal hormonal exposures can alter brain development, might some presentations of gender dysphoria reflect a neurodevelopmental substrate that affirmation-based clinical pathways do not address and may not even see? Escher's call is for retrospective cohort studies, better documentation of prenatal exposures in clinical records, and genuine scientific courage from institutions that have a poor track record of acknowledging their own errors in this domain. The episode offers a hypothesis, not a verdict, and it would be wrong to read it otherwise. But the hypothesis is grounded in a documented history of harm, in published epigenetic research, and in a statistical co-occurrence that demands explanation. That explanation is unlikely to emerge while clinical practice and research funding remain structured around assumptions that treat gender dysphoria as categorically separate from questions of neurodevelopment.
